Substrate-dependent effects of molecular-targeted anticancer agents on activity of organic anion transporting polypeptide 1B1 - PubMed (original) (raw)
. 2018 Oct;48(10):1059-1071.
doi: 10.1080/00498254.2017.1393582. Epub 2017 Nov 10.
Affiliations
- PMID: 29034773
- DOI: 10.1080/00498254.2017.1393582
Substrate-dependent effects of molecular-targeted anticancer agents on activity of organic anion transporting polypeptide 1B1
Hiroyoshi Koide et al. Xenobiotica. 2018 Oct.
Erratum in
- Correction to: Koide et al., Substrate-dependent effects of molecular-targeted anticancer agents on activity of organic anion transporting polypeptide 1B1.
[No authors listed] [No authors listed] Xenobiotica. 2018 Oct;48(10):x. doi: 10.1080/00498254.2018.1434920. Epub 2018 Feb 5. Xenobiotica. 2018. PMID: 29400115 No abstract available.
Abstract
1. Organic anion-transporting polypeptide 1B1 (OATP1B1) plays an important role in the hepatic uptake of a broad range of substrate drugs. In vitro experiments show that molecular-targeted agents do not always have similar effects on OATP1B1 activity. 2. The purpose of this study was to clarify whether the effects of molecular-targeted agents on OATP1B1 are substrate-dependent. We used OATP1B1-transfected cells to compare the effects of molecular-targeted agents on OATP1B1-mediated uptake of fluorescein (FL), 2',7'-dichlorofluorescein (DCF), atorvastatin, SN-38 and valsartan. 3. Cabozantinib, cediranib, neratinib, pazopanib, regorafenib, sorafenib and tivantinib did not affect or only slightly affected OATP1B1-mediated substrate uptake. Nilotinib and lenvatinib moderately and strongly inhibited OATP1B1-mediated substrate uptake, respectively. In contrast, afatinib stimulated OATP1B1-mediated uptake of FL and SN-38, ceritinib stimulated that of valsartan, and nintedanib stimulated that of FL and valsartan. In addition, the effects of afatinib, ceritinib and nintedanib on OATP1B1 activity differed markedly depending on the type of substrate. Afatinib, ceritinib and nintedanib had a substrate-dependent effect on OATP1B1 activity. 4. We conclude that the evaluation of OATP1B1 activity using only a single probe substrate for some molecular-targeted agents may lead to a faulty understanding of their mechanisms of drug interactions.
Keywords: Drug interaction; OATP1B1; inhibition; stimulation; transporter; tyrosine kinase inhibitor.
Similar articles
- Investigation of Fluorescein Derivatives as Substrates of Organic Anion Transporting Polypeptide (OATP) 1B1 To Develop Sensitive Fluorescence-Based OATP1B1 Inhibition Assays.
Izumi S, Nozaki Y, Komori T, Takenaka O, Maeda K, Kusuhara H, Sugiyama Y. Izumi S, et al. Mol Pharm. 2016 Feb 1;13(2):438-48. doi: 10.1021/acs.molpharmaceut.5b00664. Epub 2016 Jan 7. Mol Pharm. 2016. PMID: 26696140 - Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17β-glucuronide, estrone-3-sulfate, and sulfobromophthalein.
Izumi S, Nozaki Y, Komori T, Maeda K, Takenaka O, Kusano K, Yoshimura T, Kusuhara H, Sugiyama Y. Izumi S, et al. Drug Metab Dispos. 2013 Oct;41(10):1859-66. doi: 10.1124/dmd.113.052290. Epub 2013 Aug 6. Drug Metab Dispos. 2013. PMID: 23920221 - Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions.
Izumi S, Nozaki Y, Maeda K, Komori T, Takenaka O, Kusuhara H, Sugiyama Y. Izumi S, et al. Drug Metab Dispos. 2015 Feb;43(2):235-47. doi: 10.1124/dmd.114.059105. Epub 2014 Nov 20. Drug Metab Dispos. 2015. PMID: 25414411 - Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.
Niemi M, Pasanen MK, Neuvonen PJ. Niemi M, et al. Pharmacol Rev. 2011 Mar;63(1):157-81. doi: 10.1124/pr.110.002857. Epub 2011 Jan 18. Pharmacol Rev. 2011. PMID: 21245207 Review. - The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice.
Durmus S, van Hoppe S, Schinkel AH. Durmus S, et al. Drug Resist Updat. 2016 Jul;27:72-88. doi: 10.1016/j.drup.2016.06.005. Epub 2016 Jun 25. Drug Resist Updat. 2016. PMID: 27449599 Review.
Cited by
- Interaction between phytotherapy and oral anticancer agents: prospective study and literature review.
Clairet AL, Boiteux-Jurain M, Curtit E, Jeannin M, Gérard B, Nerich V, Limat S. Clairet AL, et al. Med Oncol. 2019 Apr 16;36(5):45. doi: 10.1007/s12032-019-1267-z. Med Oncol. 2019. PMID: 30993543 Review. - Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors.
Garrison DA, Talebi Z, Eisenmann ED, Sparreboom A, Baker SD. Garrison DA, et al. Pharmaceutics. 2020 Sep 9;12(9):856. doi: 10.3390/pharmaceutics12090856. Pharmaceutics. 2020. PMID: 32916864 Free PMC article. Review. - Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.
Hulin A, Stocco J, Bouattour M. Hulin A, et al. Clin Pharmacokinet. 2019 Aug;58(8):983-1014. doi: 10.1007/s40262-019-00740-w. Clin Pharmacokinet. 2019. PMID: 31093928 Review. - Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
Hirota T, Muraki S, Ieiri I. Hirota T, et al. Clin Pharmacokinet. 2019 Apr;58(4):403-420. doi: 10.1007/s40262-018-0689-7. Clin Pharmacokinet. 2019. PMID: 29915924 Review. - Regulation of OATP1B1 Function by Tyrosine Kinase-mediated Phosphorylation.
Hayden ER, Chen M, Pasquariello KZ, Gibson AA, Petti JJ, Shen S, Qu J, Ong SS, Chen T, Jin Y, Uddin ME, Huang KM, Paz A, Sparreboom A, Hu S, Sprowl JA. Hayden ER, et al. Clin Cancer Res. 2021 Aug 1;27(15):4301-4310. doi: 10.1158/1078-0432.CCR-21-0023. Epub 2021 Mar 4. Clin Cancer Res. 2021. PMID: 33664059 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources